| Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ... American Journal of Gastroenterology 110 (9), 1324-1338, 2015 | 1951 | 2015 |
| Tofacitinib as induction and maintenance therapy for ulcerative colitis WJ Sandborn, C Su, BE Sands, GR D’Haens, S Vermeire, S Schreiber, ... New England Journal of Medicine 376 (18), 1723-1736, 2017 | 1878 | 2017 |
| Erratum: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (Nature Genetics (2011) 43 (246-252)) CA Anderson, G Boucher, CW Lees, A Franke, M D'Amato, KD Taylor, ... Nature genetics 43 (9), 2011 | 1771 | 2011 |
| Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 CA Anderson, G Boucher, CW Lees, A Franke, M D'Amato, KD Taylor, ... Nature genetics 43 (3), 246-252, 2011 | 1771 | 2011 |
| Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial J Panés, D García-Olmo, G Van Assche, JF Colombel, W Reinisch, ... The Lancet 388 (10051), 1281-1290, 2016 | 1087 | 2016 |
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis WJ Sandborn, S Ghosh, J Panes, I Vranic, C Su, S Rousell, ... New England Journal of Medicine 367 (7), 616-624, 2012 | 932 | 2012 |
| Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines J Panes, Y Bouhnik, W Reinisch, J Stoker, SA Taylor, DC Baumgart, ... Journal of Crohn's and Colitis 7 (7), 556-585, 2013 | 777 | 2013 |
| Development of the Crohn's disease digestive damage score, the Lemann score B Pariente, J Cosnes, S Danese, WJ Sandborn, M Lewin, JG Fletcher, ... Inflammatory bowel diseases 17 (6), 1415-1422, 2011 | 732 | 2011 |
| Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations G Van Assche, A Dignass, B Bokemeyer, S Danese, P Gionchetti, ... Journal of Crohn's and Colitis 7 (1), 1-33, 2013 | 541 | 2013 |
| Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease J Panés, D García-Olmo, G Van Assche, JF Colombel, W Reinisch, ... Gastroenterology 154 (5), 1334-1342. e4, 2018 | 525 | 2018 |
| Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial S Vermeire, S O'Byrne, M Keir, M Williams, TT Lu, JC Mansfield, CA Lamb, ... The Lancet 384 (9940), 309-318, 2014 | 520 | 2014 |
| Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled … BG Feagan, WJ Sandborn, G D'Haens, J Panés, A Kaser, M Ferrante, ... The Lancet 389 (10080), 1699-1709, 2017 | 483 | 2017 |
| Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus A Bourreille, A Ignjatovic, L Aabakken, EV Loftus Jr, R Eliakim, ... Endoscopy 41 (07), 618-637, 2009 | 395 | 2009 |
| Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials J Panés, WJ Sandborn, S Schreiber, BE Sands, S Vermeire, G D'Haens, ... Gut 66 (6), 1049-1059, 2017 | 392 | 2017 |
| Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis RM Perez-Ayuso, JM Pique, J Bosch, E Quintero, R Valderrama, ... The Lancet 337 (8755), 1431-1434, 1991 | 355 | 1991 |
| A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease WJ Sandborn, S Ghosh, J Panes, I Vranic, W Wang, W Niezychowski, ... Clinical gastroenterology and hepatology 12 (9), 1485-1493. e2, 2014 | 349 | 2014 |
| Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease B Pariente, JY Mary, S Danese, Y Chowers, P De Cruz, G D’Haens, ... Gastroenterology 148 (1), 52-63. e3, 2015 | 346 | 2015 |
| Regional differences in constitutive and induced ICAM-1 expression in vivo J Panes, MA Perry, DC Anderson, A Manning, B Leone, G Cepinskas, ... American Journal of Physiology-Heart and Circulatory Physiology 269 (6 …, 1995 | 342 | 1995 |
| Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project I Cleynen, JR González, C Figueroa, A Franke, D McGovern, M Bortlík, ... Gut 62 (11), 1556-1565, 2013 | 324 | 2013 |
| Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease J Panés, A López–SanRomán, F Bermejo, V García–Sánchez, M Esteve, ... Gastroenterology 145 (4), 766-774. e1, 2013 | 302 | 2013 |
